Nora B. Sandorfi

Rheumatology

3400 Civic Center Boulevard
South Pavilion, 1st Floor
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis.

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis.

Journal: Arthritis care & research

Published: November 21, 2025

Association of Type III and Type VI Collagen Neoepitopes With Disease Severity in Systemic Sclerosis.

Association of Type III and Type VI Collagen Neoepitopes With Disease Severity in Systemic Sclerosis.

Journal: The Journal of rheumatology

Published: November 05, 2025

Rebuttal for letter to the editor from Miss Nassar and Dr Thombs regarding: "A systematic review of prevalence and predictors of depression in systemic sclerosis based on the CES-D, BDI, and PHQ-9 self-assessment questionnaires".

Rebuttal for letter to the editor from Miss Nassar and Dr Thombs regarding: "A systematic review of prevalence and predictors of depression in systemic sclerosis based on the CES-D, BDI, and PHQ-9 self-assessment questionnaires".

Journal: Clinical rheumatology

Published: June 16, 2025

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.

Journal: Annals of the American Thoracic Society

Published: April 10, 2025

Diagnostic Use of Testing for Novel Murine Autoantibodies for Sjögren Disease in the Rheumatology Outpatient Setting.

Diagnostic Use of Testing for Novel Murine Autoantibodies for Sjögren Disease in the Rheumatology Outpatient Setting.

Journal: Arthritis care & research

Published: March 14, 2025

Long-term outcomes of vascular grafting of medium-sized vessels of wrist and hand in systemic sclerosis patients with medication refractory Raynaud's.

Long-term outcomes of vascular grafting of medium-sized vessels of wrist and hand in systemic sclerosis patients with medication refractory Raynaud's.

Journal: Journal of scleroderma and related disorders

Published: January 16, 2025

A systematic review of prevalence and predictors of depression in systemic sclerosis based on the CES-D, BDI, and PHQ- 9 self-assessment questionnaires.

A systematic review of prevalence and predictors of depression in systemic sclerosis based on the CES-D, BDI, and PHQ- 9 self-assessment questionnaires.

Journal: Clinical rheumatology

Published: January 14, 2025

Psychometric Evaluation of the Scleroderma Skin Questionnaire: A Novel Patient-Reported Outcome for Skin Disease in Patients With Systemic Sclerosis.

Psychometric Evaluation of the Scleroderma Skin Questionnaire: A Novel Patient-Reported Outcome for Skin Disease in Patients With Systemic Sclerosis.

Journal: The Journal of rheumatology

Published: December 09, 2024

Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts.

Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 09, 2024

The Impact of Donor-Recipient Human Leukocyte Antigen Matching on Bronchiolitis Obliterans-Free Survival Among Lung Transplant Recipients With Connective Tissue Diseases.

The Impact of Donor-Recipient Human Leukocyte Antigen Matching on Bronchiolitis Obliterans-Free Survival Among Lung Transplant Recipients With Connective Tissue Diseases.

Journal: Clinical transplantation

Published: April 19, 2024

Health Care Utilization: What Is the Cost of Caring for Scleroderma?

Health Care Utilization: What Is the Cost of Caring for Scleroderma?

Journal: Rheumatic diseases clinics of North America

Published: April 07, 2023

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.

Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: February 22, 2023

Showing 1-12 of 25

Last Updated: 09/26/2026